Zynex (NASDAQ:ZYXI) Issues Q4 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter earnings guidance on Thursday. The company provided EPS guidance of at least $0.09 for the period, compared to the consensus EPS estimate of $0.10. The company issued revenue guidance of at least $53.6 million, compared to the consensus revenue estimate of $53.30 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Zynex in a report on Wednesday, September 4th. Royal Bank of Canada decreased their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Zynex Stock Performance

ZYXI stock traded up $0.23 during mid-day trading on Thursday, reaching $8.59. 151,003 shares of the stock traded hands, compared to its average volume of 173,447. The company has a quick ratio of 3.22, a current ratio of 4.06 and a debt-to-equity ratio of 1.79. Zynex has a 52 week low of $7.04 and a 52 week high of $13.77. The business has a 50-day moving average of $7.96 and a two-hundred day moving average of $9.23. The firm has a market capitalization of $272.65 million, a PE ratio of 47.72 and a beta of 0.54.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Zynex had a net margin of 3.12% and a return on equity of 14.15%. The firm had revenue of $49.88 million for the quarter, compared to the consensus estimate of $51.99 million. During the same quarter last year, the company earned $0.09 earnings per share. The firm’s revenue was up 11.0% on a year-over-year basis. As a group, equities analysts predict that Zynex will post 0.2 EPS for the current fiscal year.

Insider Activity at Zynex

In related news, COO Anna Lucsok sold 8,083 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the sale, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Joshua R. Disbrow bought 7,000 shares of Zynex stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now owns 72,000 shares in the company, valued at approximately $599,040. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Anna Lucsok sold 8,083 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now owns 16,980 shares of the company’s stock, valued at approximately $136,349.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 52.13% of the stock is owned by corporate insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.